by The Europe cell culture market size was estimated at around USD 5.97 billion in 2022 and it is projected to hit around USD 16.42 billion by 2032, growing at a CAGR of 10.65% from 2023 to 2032.
Key Pointers
- By Product, the consumables segment held the largest revenue share of 58% in 2022.
- By Product, the instruments segment is predicted to grow at the remarkable CAGR between 2023 to 2032.
- By Application, the biopharmaceutical production segment contributed the largest market share in 2022.
- By Application, the diagnostics segment is predicted to grow at the remarkable CAGR over the forecast period.
The Europe cell culture market is a dynamic and rapidly evolving sector within the broader life sciences industry. Cell culture, a foundational technique in biomedical research and biopharmaceutical production, involves the cultivation of cells outside their natural environment for various scientific and commercial purposes. This overview provides a snapshot of the key facets shaping the landscape of the cell culture market in Europe.
Get a Sample: https://www.visionresearchreports.com/report/sample/40983
Market Growth
The growth of the Europe cell culture market is propelled by several key factors. Firstly, the increasing emphasis on biopharmaceuticals, such as monoclonal antibodies and therapeutic proteins, is a significant driver. The demand for advanced cell culture techniques has surged in tandem with the rising prominence of biopharmaceutical research and production. Additionally, continuous innovation and technological advancements, including 3D cell culture systems and automation, contribute to the market’s expansion by enhancing precision and scalability in cell culture processes. The region’s heightened focus on research and development across academic, pharmaceutical, and research institutions further fuels the demand for diverse cell culture applications. Moreover, the exploration of regenerative medicine and breakthroughs in stem cell research plays a pivotal role, creating additional avenues for growth. In summary, the Europe cell culture market is thriving due to the increasing relevance of biopharmaceuticals, ongoing technological innovations, a robust research environment, and the exploration of regenerative medicine applications.
Report Scope of the Europe Cell Culture Market
| Report Coverage | Details |
| Market Size in 2022 | USD 5.97 billion |
| Revenue Forecast by 2032 | USD 16.42 billion |
| Growth rate from 2023 to 2032 | CAGR of 10.65% |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Market Dynamics
Drivers
- Biopharmaceutical Emphasis: The Europe cell culture market is driven by a pronounced emphasis on biopharmaceuticals, including monoclonal antibodies, therapeutic proteins, and vaccines. The growing demand for these advanced pharmaceuticals fuels the need for efficient and scalable cell culture techniques.
- Research and Development Surge: The region is experiencing a surge in research and development activities across academic institutions, pharmaceutical companies, and research organizations. This heightened R&D focus creates a strong demand for diverse cell culture applications, further propelling market expansion.
Restraints
- Initial Setup Costs: The establishment of advanced cell culture facilities incurs substantial initial setup costs. This financial barrier can be a restraint for smaller entities entering the market. Despite the potential long-term benefits, the upfront investment may limit the entry of some players into the cell culture market.
- Complexity in Personalized Medicine: While personalized medicine offers significant opportunities, its complexity poses challenges. Tailoring treatments based on individual patient characteristics requires intricate understanding and customization, making it a potential restraint for broader market adoption.
Opportunities
- Continued Technological Innovation: The cell culture market can capitalize on opportunities arising from continued technological innovation. Investing in research and development to further refine and enhance cell culture technologies, such as 3D cell culture systems and automation, can unlock new avenues for market growth and differentiation.
- Market Expansion through Compliance: Stringent regulatory compliance, while a challenge, also serves as an opportunity for market expansion. Companies that proactively adhere to regulatory standards can build credibility and gain a competitive edge in the market, positioning themselves as reliable and compliant partners.
Product Insights
On the basis of product, the market is segmented into instruments and consumables. The consumables segment accounted for the largest market share of 58% in 2022 and is expected to witness the fastest growth during the forecast period. The consumables segment includes reagents, sera, and media. The segment dominance is primarily due to recurring demand and purchase of consumables. Moreover, the increasing R&D expenditure by biopharmaceuticals and biotechnology firms to develop sophisticated biologics, such as monoclonal antibodies & vaccines, is expected to propel the segment growth. In addition, industry participants are increasing the offerings in this segment. For instance, in May 2023, Lonza, a key industry player, introduced TheraPEAK T-VIVO Cell Culture Medium for developing cell therapies.
The instruments segment is expected to exhibit significant growth over the forecast period due to the increasing launches of innovative systems like cryostorage instruments, biosafety instruments, and pipetting equipment. Companies are constantly innovating to introduce novel instruments. For instance, in October 2023, Sartorius announced the launch of Picus 2 Electronic Pipette, the newest addition to its electronic pipette portfolio.
Application Insights
On the basis of application, the market is segmented into biopharmaceutical production, diagnostics, drug development, tissue culture & engineering, toxicity testing, cell & gene therapy, and other applications. The biopharmaceutical production segment held the largest revenue share in 2022. Cell culture technology is heavily utilized in the biotechnology sector for a variety of purposes, including bioprocessing, drug development, and biomanufacturing. Mammalian cell cultures are primarily used in the production of biopharmaceuticals, and the growing demand for nonconventional therapeutic options has led to a substantial increase in the bioproduction of genetically enhanced drugs. Thus, the demand for various cell culture consumables, such as cell culture media, is expected to increase. Furthermore, increasing availability of a variety of media types in serum-free and animal component-free forms has led to increased adoption of cell culture media in bioprocessing operations. These factors are expected to significantly boost segment growth over the forecast period.
On the contrary, the diagnostics segment is predicted to grow at the remarkable CAGR over the forecast period. Cell cultures can be used in metabolomics to identify biomarkers of pathologically relevant conditions. Moreover, metabolic pathways that lead to the production of such biomarkers can also be identified to determine underlying metabolic disorders. In addition, metabolites also play a vital role in diagnosing cancer and its recurrence, which increases the scope of applications for cell culture media products. Thus, with the rising prevalence of cancer across the region coupled with the increasing application of cell culture products for disease diagnosis, the segment is expected to witness growth over the forecast period.
Key Companies
- Danaher Corporation
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Sartorius AG
- Corning Incorporated
- BD
- Avantor, Inc.
- Eppendorf SE
- PromoCell GmbH
- Bio-Techne
Recent Developments
Molecular Devices, LLC, a division of Danaher Corporation, unveiled the CellXpress.ai Automated Cell Culture System in October 2023. This device has patent-pending technology that makes use of machine learning to simplify the challenging procedures involved in feeding and passaging cells.
Thermo Fisher Scientific and Celltrio established a partnership in February 2023 to offer clients in the biotherapeutics industry a fully automated cell culture system.
A new-to-the-world cell sorting apparatus with two ground-breaking breakthroughs that enable researchers to reveal more detailed information about cells than would typically be possible via flow cytometry research was revealed by BD in May 2023.
Europe Cell Culture Market Report Segmentations:
By Product
- Consumables
- Media
- Serum-free Media
- CHO Media
- BHK Medium
- Vero Medium
- HEK 293 Media
- Other Serum-free Media
- Classical Media
- Stem Cell Culture Media
- Specialty Media
- Chemically Defined Media
- Other Cell Culture Media
- Sera
- Fetal Bovine Serum
- Others
- Reagents
- Albumin
- Others
- Serum-free Media
- Media
- Instruments
- Culture Systems
- Incubators
- Centrifuges
- Cryostorage Equipment
- Biosafety Equipment
- Pipetting Instruments
By Application
- Biopharmaceutical Production
- Monoclonal Antibodies
- Vaccine Production
- Other Therapeutic Proteins
- Drug Development
- Diagnostics
- Tissue Culture & Engineering
- Cell & Gene Therapy
- Toxicity Testing
- Other Applications
